Latest Quarterly Report
Filed: 2026-04-29
Key Insights
- Company completed a SPAC merger and subsequent financing activities in 2025, including a pre-merger sale of common stock and warrants (June 2025) and a PIPE financing (December 2025), indicating active capital raising post-merger.
- Multiple equity incentive plans were established or activated in 2025-2026 (2024 Equity Incentive Plan, 2025 Stock Incentive Plan, 2025 Employment Inducement Plan, and 2025 Employee Stock Purchase Plan), suggesting preparation for scaled operations and employee retention as a public company.
- The filing shows Series Seed Convertible Preferred Stock and Series A Preferred Stock tranches from 2024-2025, with convertible notes payable indicating reliance on debt financing prior to and concurrent with equity raises, typical for early-stage biotech companies.
- As of Q1 2026, the company maintains convertible notes payable and multiple warrant instruments outstanding, reflecting a complex capital structure common to recently public biotech firms still in development stages without apparent product revenue.